OPTIMIZING NON-ADDICTIVE DRUG DELIVERY
IN THE MANAGEMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery platforms across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate.
Our transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to optimize the efficacy of our non-addictive pain management pipeline and our CNS disorder pipeline.
Virpax is developing non-addictive pain treatment options that allow for more individualized patient care. More treatment options may help increase better health outcomes; including better, rehabilitation, post-surgery care, functionality, quality of life and may help patients get back to work.
Virpax is publicly traded on
(Nasdaq: VRPX)
Virpax® Pharmaceuticals is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
View our presentation
OPTIMIZING NON-ADDICTIVE DRUG DELIVERY
IN THE TREATMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES
Envelta™
Molecular Envelope Enkephalin Powder
Envelta is a patented intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.
We’re seeking global partners to sublicense OTC, Device, and Animal Health
We engaged Destum Partners to help us connect the world with promising products.
Recent Press Releases
Recent Media
OUR MISSION
Our mission is to use our proprietary delivery platforms to optimize the efficacy of our non-addictive post operative pain, severe pain and CNS disorder product candidates.
We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide, including rare and orphan diseases.
